. Author manuscript; available in PMC: 2008 May 2.

Published in final edited form as: J Subst Abuse Treat. 2007 Feb 22;32(4):321–329. doi: 10.1016/j.jsat.2006.05.021

Table 2.

Logistic regression results predicting buprenorphine adoption as a function of organizational characteristics and CTN exposure (N=898)

Variable	b	Odds ratio
Predominantly public revenues	−.181
For-profit structure	.205
Accredited by JCAHO or CARF	.499
Surveys buyers, suppliers, or both	−.256
Offers detoxification services	1.279	3.594^a
FTEs (log)	−.011
Physician(s) on staff or on contract	1.370	3.936^a
Percent master's level counselors	.667
Percent primary opiate clients	.009	1.009^b
Period of survey	.146
Program experience in clinical research	.121
Program not a CTN member (reference category)	---
Program in CTN but not in buprenorphine trials	−.236
Program participated in CTN buprenorphine trial(s)	1.640	5.153^a
Constant	−3.874

Note. Pseudo-R² (.155) calculated as (model chi sq / original -2LL) (Hosmer & Lemeshow, 1989).

p<.01

p<.05